Brief: Advaxis Announces Updated Survival Data In Phase 1/2 ADXS-PSA Trial

Ayala Pharmaceuticals

13/02/2020 14:25

Feb 13 (Reuters) - Advaxis Inc  ADXS.O :
    * ADVAXIS ANNOUNCES UPDATED SURVIVAL DATA IN PHASE 1/2
ADXS-PSA
TRIAL AT THE ASCO GENITOURINARY CANCERS SYMPOSIUM
    * ADVAXIS INC - MEDIAN OVERALL SURVIVAL OF 33.7 MONTHS IN
ALL
PATIENTS TREATED WITH ADXS-PSA IN COMBINATION WITH KEYTRUDA
    * ADVAXIS - COMBINATION OF ADXS-PSA AND KEYTRUDA APPEARED TO
BE
WELL-TOLERATED, TO DATE, WITH NO ADDITIVE TOXICITY OBSERVED
    * ADVAXIS - MEDIAN SURVIVAL OF 16.4 MONTHS FOR ADVANCED
PROSTATE
CANCER PATIENTS WITH VISCERAL METASTASES TREATED WITH ADXS-PSA
COMBINED WITH KEYTRUDA

Source text for Eikon:  ID:nGNXW2Z3S 
Further company coverage:  ADXS.O 

 ((Reuters.Briefs@thomsonreuters.com;))